All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by major social, communication and behavioural challenges. More specifically, individuals with ASD emit repetitive and restricted behavioural patterns as well as atypical social tendencies, which greatly impacts their daily functioning abilities \[[@pone.0232351.ref001]\].

The cause of ASD is still unclear and it is assumed that both the environmental and genetic factors together influence the risk of ASD occurrence. ASD as a part of a genetic syndrome is identified in about 10% of all ASD cases and such cases are usually associated with malformations and/or dysmorphic characteristics \[[@pone.0232351.ref002]--[@pone.0232351.ref004]\]. The genetic contribution to ASD is undoubtedly significant as the concordance rates for monozygotic twins is 58% for male and 60% for female, while for di-zygotic twins it is 21% for male pairs and 27% for female pairs \[[@pone.0232351.ref005]\]. The concordance rates also show that other factors influence the occurrence of ASD such as epigenetic regulation and environment. Epigenetic gene regulation is an essential mechanism for normal brain development \[[@pone.0232351.ref006]\] and anomalies in the molecules responsible for this mechanism are known to cause various neurodevelopmental disorders including autism \[[@pone.0232351.ref007]--[@pone.0232351.ref012]\]. Moreover, prenatal exposure to some of the substances which have been shown to increase the risk of ASD are, among others, thalidomide, misoprostol, valproic acid and chlorpyrifos \[[@pone.0232351.ref013]\]. Today we know that the effects of prenatal exposure to alcohol, pollution, infections and inflammations, as well as assisted deliveries, have a negative impact on later health and development of a child \[[@pone.0232351.ref014], [@pone.0232351.ref015]\].

The prevalence of ASD, all over the world, has had an increasing trend \[[@pone.0232351.ref016], [@pone.0232351.ref017]\]. The latest report on prevalence in the USA shows 1 in 59 children with ASD \[[@pone.0232351.ref018]\]. The worldwide prevalence of ASD is estimated to be 1--2% of the population, however, prevalence varies from country to country, mainly depending on how advanced the diagnostic system is and the availability of screening and diagnostic tools \[[@pone.0232351.ref018]--[@pone.0232351.ref022]\]. In order to detect and diagnose ASD, the American Academy of Paediatrics and the US Preventative Service Task Force suggest the usage of valid and reliable screening and diagnostic tools \[[@pone.0232351.ref023], [@pone.0232351.ref024]\]. Unfortunately, most of these tools are not translated, validated or financially accessible for most low and middle income countries (LMIC) where it has been estimated that 250 million children younger than 5 years are at risk of not achieving full developmental potential \[[@pone.0232351.ref001],[@pone.0232351.ref025]\]. Early intervention shows significant outcomes for children with ASD which mostly depends on the early detection and diagnosis of the disorder \[[@pone.0232351.ref026]\]. Trends of late diagnosis have to be replaced by early diagnosis due to the short window of human brain development, because of which the best results of early intervention are achieved by the age of 5 \[[@pone.0232351.ref027],[@pone.0232351.ref028]\].

Bosnia and Herzegovina (B&H) is classified as a mid-income country where parents of children with developmental disorders often encounter difficulties in getting an early diagnosis for their child. Diagnosis in B&H is usually made by a process of exclusion (usually by completing various unnecessary medical tests such as MRI, EEG etc.) and based, in most cases, on clinical evaluation. Experts from various countries point out the need for all countries to develop population-based detection, screening and evidence-based intervention for children in order to increase a chance for social inclusion of all \[[@pone.0232351.ref029]\]. Recently, a cheap and efficient model for diagnosing ASD emerged in the field of genetics where microRNA analysis showed promising results in distinguishing children with ASD from their typically and atypically developing peers \[[@pone.0232351.ref030]\]. This combined with validated screening tools could offer an affordable solution for LMIC where access to expensive diagnostic tools hinders the process of diagnosis and therefore intervention itself. Genetic analyses can be performed on samples of various origins, but for the sake of diagnosis, these sources are mostly blood, saliva or buccal swabs. Chosen source for this particular application would be saliva due to the specificity of the target population. ASD individuals are restless and taking their blood sample or buccal swab is highly demanding even for experienced individuals. On the other hand, saliva can be collected by simple means of saliva collection which is easy to accomplish even with extreme cases of ASD and DD \[[@pone.0232351.ref031]--[@pone.0232351.ref034]\].

MicroRNAs (miRNAs) are a group of relatively small (around 21 nucleotides) noncoding transcripts that can modify cellular messenger RNAs (mRNAs) and protein levels by interacting with specific mRNAs. The interaction of miRNAs with mRNAs usually occurs at the 3' untranslated region (UTR) which results in mRNA degradation or repression of translation \[[@pone.0232351.ref035], [@pone.0232351.ref036]\] through partial sequence complementation \[[@pone.0232351.ref037]\]. It is thought that around 10--30% of all human genes could be miRNA targets \[[@pone.0232351.ref038], [@pone.0232351.ref039]\].

MiRNAs have an important role in central nervous system development and function \[[@pone.0232351.ref040], [@pone.0232351.ref041]\]. Therefore, it is not surprising that the dysregulation of miRNAs is connected to changes in behaviour and cognition observed in many neuropsychiatric disorders \[[@pone.0232351.ref042]\]. More specifically, miRNAs have important functions in neurogenesis, synaptogenesis and neuronal migration \[[@pone.0232351.ref043]\]. Usually the main function of miRNAs in these processes affect the spatial localization or compartmentalization of protein translation in different neuronal subregions, such as axons, dendrites, and synapses \[[@pone.0232351.ref044],[@pone.0232351.ref045]\]. MiRNAs have been found to be dysregulated in children with ASD in various analysed biomaterials such as post-mortem cerebellar cortex \[[@pone.0232351.ref046]\], several post-mortem's Brodmann's areas \[[@pone.0232351.ref047],[@pone.0232351.ref048]\], serum \[[@pone.0232351.ref049]\], peripheral blood \[[@pone.0232351.ref050],[@pone.0232351.ref051]\], whole blood \[[@pone.0232351.ref052]\], saliva \[[@pone.0232351.ref053]\], olfactory mucosal stem cells \[[@pone.0232351.ref054]\], lymphoblast cell lines \[[@pone.0232351.ref055]--[@pone.0232351.ref057]\].

Successful models for diagnosing ASD utilizing various RNA molecules (miRNA, piRNA, snoRNA etc) obtained from the saliva have been created. The study whose model focused entirely on miRNAs obtained an accuracy higher than 95% \[[@pone.0232351.ref053]\], while the study which generated a model on various types of RNA molecules obtained a positive predictive value of 91% \[[@pone.0232351.ref058]\].

In order to explore affordable and quick screening models and detection of developmental disorders including ASD in B&H, we have performed a pilot study on molecular biomarkers as potential detection of atypical development. The aim of this study was to evaluate expression levels of 14 selected miRNAs from saliva of children with suspected developmental disorder and to test their ability to detect developmental disorders (DD) including ASD. The proposed panel was previously tested by Hicks et al., 2016 \[[@pone.0232351.ref053]\] using Next Generation Sequencing, while our method of choice was qRT-PCR, as a relatively cheap method found in most diagnostics labs in low to mid-income countries such as B&H.

Materials and methods {#sec002}
=====================

Participants and assessment {#sec003}
---------------------------

This study was approved by the EDUS Institutional Review Board for the Protection of Human Subjects (IRB) for all project activities. All participants were recruited through the Non-governmental organization EDUS-Education for All from Sarajevo, the capital of B&H. Informed written parental consent was obtained for a total of 81participants out of 126 that were enrolled in the EDUS preschool program during the school year 2018/2019. The EDUS preschool program is based on the CABAS® system (Comprehensive Application of Behavior Analysis), an evidence-based approach to assessment and treatment of Developmental Disorders and Autism Spectrum Disorder \[[@pone.0232351.ref059]--[@pone.0232351.ref063]\]. Children from all over B&H are enrolled in the program receiving services in developmental screening, assessment and/or treatment. One participant was excluded from the study because of the inability to collect saliva resulting in the final sample size of 80 participants consisted of children with detected developmental delays/disorders (DD) (n = 55) and typically developing (TD) pre-school children with no previously detected developmental problems were classified as the control group (n = 25) ([Table 1](#pone.0232351.t001){ref-type="table"}). The control sample was recruited from several public kindergartens for typically developing children. All data in this study were collected during the period from March to May 2018.

10.1371/journal.pone.0232351.t001

###### Characteristics of the control sample.

![](pone.0232351.t001){#pone.0232351.t001g}

  Characteristics   *n* (%)       Mean Age expressed in months
  ----------------- ------------- --------------------------------------
  Male              11 (44.0%)    74.9 (SD = 14.4, Min = 54, Max = 95)
  Female            14 (56.0%)    64.8 (SD = 12.5, Min = 42, Max = 79)
  Total             25 (100.0%)   69.3 (SD = 14, Min = 42, Max = 95)

In order to classify participants into DD and TD groups all 80 children went through a developmental screening with the EDUS Developmental Behavioural Scales (EDUS-DBS) \[[@pone.0232351.ref064]\]. EDUS-DBS covers all five developmental areas: speech and communication, motor development (gross and fine), cognitive development, social-emotional development, and self-help/adaptive skills. The EDUS-DBS screening outcome indicates, for each developmental area separately, whether the child is developing typically or atypically for their chronological age. Children who showed a developmental delay in at least one area mentioned above were selected into the group of children with DD, and children that did not show developmental delays were selected into the group of TD children. The second step was to screen the group of children detected with DD for Autism symptoms with the Childhood Autism Rating Scale, Second edition (CARS-II) \[[@pone.0232351.ref065]\]. The final raw score of CARS-II classifies each child into one of the three different autism symptoms severity groups: Minimal-to-No Symptoms of ASD, Mild-to-Moderate Symptoms of ASD, and Severe Symptoms of ASD. The third step consisted of clinical observations conducted by an experienced child psychiatrist in the field of ASD. By taking into account the direct observation of the child and information collected from parents about their child's developmental history, the child psychiatrist concluded two possible outcomes: ASD or DD different from ASD. The child psychiatrist had no access to the CARS-II scores of the DD sample when making conclusions.

After considering the outcomes of the CARS-II and clinical observations of the child psychiatrist, the group of children with DD was divided into two groups: children identified with ASD (n = 39) and children with other DD different from ASD (n = 16). Children identified with ASD showed CARS-II scores that fall into the Mild-to-Moderate and Severe ASD Symptoms category, and children identified with other DD (different from ASD) showed scores that fall into the Minimal-to-No Symptoms of ASD CARS-II category ([Table 2](#pone.0232351.t002){ref-type="table"}). Clinical observations were conducted for 26 children (47.3%) and showed 100% concordance between Child Psychiatrists observations and CARS-II results with the CARS-II classifications (i.e. CARS-II scores indicated Mild-To-Moderate or Severe Symptoms of ASD and clinical opinion concluded ASD, CARS-II scores indicated Minimal-to-No Symptoms of ASD and Clinical opinion concluded that it is another DD different from ASD) ([Table 2](#pone.0232351.t002){ref-type="table"}). Children for clinical observations from a Child Psychiatrist were selected randomly out of the whole DD sample (n = 55). No predetermined criteria for selection of participants was used.

10.1371/journal.pone.0232351.t002

###### Characteristics of the DD participants.
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  Characteristics                                Developmental disorder                        Autism Spectrum disorder
  ---------------------------------------------- --------------------------------------------- ---------------------------------------------
  **Gender**                                                                                   
  Male                                           14 (87.5%)                                    25 (64.1%)
  Female                                         2 (12.5%)                                     14 (35.9%)
  Total                                          16 (100.0%)                                   39 (100.0%)
  **Mean age of Participants**                                                                 
  Male                                           60.4 months (SD = 12.6, Min = 38, Max = 80)   63.2 months (SD = 15.1, Min = 39, Max = 92)
  Female                                         61 months (SD = 5.6, Min = 57, Max = 65)      56.5 months (SD = 14.7, Min = 37, Max = 85)
  Total                                          60.4 months (SD = 11.8, Min = 38, Max = 80)   60.8 months (SD = 15.1, Min = 37, Max = 92)
  **Detected developmental delay**                                                             
  1 Developmental Area                           1 (6.2%)                                      1 (2.6%)
  3 Developmental Areas                          2 (12.5%)                                     1 (2.6%)
  4 Developmental Areas                          3 (18.8%)                                     5 (12.8%)
  5 Developmental Areas                          10 (62.5%)                                    32 (82.0%)
  Total                                          16 (100.0%)                                   39 (100.0%)
  **CARS-II screening outcomes**                                                               
  Minimal-to-No Symptoms of ASD                  16 (100.0%)                                   0 (0.0%)
  Mild-to-Moderate Symptoms of ASD               0 (0.0%)                                      12 (30.8%)
  Severe Symptoms of ASD                         0 (0.0%)                                      27 (69.2%)
  Total                                          16 (100.0%)                                   39 (100.0%)
  **Clinical opinion from Child Psychiatrist**                                                 
  Male observed                                  5                                             14
  Female observed                                1                                             6
  Mean age                                       66.5 (SD = 3,0 Min = 62, Max = 70)            61.9 (SD = 14.3, Min = 37, Max = 91)
  Concluded ASD                                  0                                             20
  Concluded other DD                             6                                             0
  Sample covered                                 6 (37.5%)                                     20 (51.3%)

Molecular analysis {#sec004}
------------------

A total of 80 saliva samples were collected in a non-fasting state after rinsing with tap water with at least 30 minutes timespan from the last meal. Approximately 2 mLs of saliva were obtained, per manufacturer's instructions, using Samplifybio saliva collection kit (Samplfybio, Beverly, MA) and stored at room temperature until processing.

For the purpose of analysing 14 miRNAs of interest (miR-628-5p, miR-127-3p, miR-27a-3p, miR-335-3p, miR-2467-5p, miR-30e-5p, miR-28-5p, miR-191-5p, miR-23-3p, miR-3529-5p, miR-218-5p, miR-7-5p, miR-32-5p and miR-140-3p), total RNA was isolated from saliva samples using the mirVANA isolation kit (Invitrogen^™^), according to the manufacturer's instructions. The purity of isolated RNA was determined by OD260/280 using a Nanodrop (Thermo Scientific, Worcester, MA).

The miRNAs of interest were reversely transcribed using TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems^™^ Foster City, CA) and specific miRNA reverse transcription (RT) primers, on GS1 Thermal Cycler System (G-Strom) and SimpliAmp Thermal Cycler (Applied Biosystems^™^ Foster City, CA) according to the manufacturer's instructions.

After reverse transcription, due to smaller amounts of RNA within the samples, pre-amplification was performed. For pre-amplification, a custom primer pool was prepared with 14 miRNAs of interest. The total volume of the primer pool contained 70 μL of TaqMan MicroRNA Assay + 430 ddH~2~0 for a total of 500 μL. In the mastermix for the pre-amplification reaction, for each sample, we used 1.9 μL of pre-amplification primer pool, 0.13 μL of AmpliTaq Gold, 0.75 μL of MgCl, 1.25 μL of 10x PCR Buffer Gold, 1.0 μL of dNTPs and 6.22 μL of ddH~2~0.

The quantification of targeted miRNAs was performed using TaqMan MicroRNA Assay (Applied Biosystems^™^ Foster City, CA) on Agilent (Stratagene, La Jolla, CA) MX3005P Multiplex QPCR Real-time Thermal Cycler. For the purpose of quantification of targeted miRNAs, a mastermix was made with 5 μL of TM Universal mastermix, 0.5 μL of 20x TM Micro RNA Array assay for a particular miRNA and 4.30 μL of ddH~2~0. The total mastermix volume was 9.80 μL. The qPCR reaction was performed on all miRNAs individually. For each miRNA the appropriate 20x TM Micro RNA Array assay was used. The dye used for miRNA comparative quantitation was FAM. Within each plate a calibrator well was selected for the purpose of normalization of data. Data was organized for each miRNA and necessary replicates were performed.

Statistical analysis {#sec005}
--------------------

Normalization of expression data was performed using Delta Delta Ct, as suggested by \[[@pone.0232351.ref066]\], which is calculated according to formula: (original Ct value of a sample-calibrator value of the miRNA)---(calibrator of the miRNA from the sample--calibrator of the normalizing miRNA). The normalizing miRNA used in this study was miR-191-5p \[[@pone.0232351.ref067]\].

Outliers were determined using the Grubbs test via Xlstat add-on with Microsoft Office Excel program. Since obtained results have normalized Ct values, criteria for the classification of an outlier was used. Hence, all normalized expression data values with a z-score over 1.5, for both tails, were classified as outliers. The 1.5 z-score threshold was chosen because the Ct values above that threshold are too high or too low in order to be considered valid \[[@pone.0232351.ref068]\]. The data was tested for normal distribution using Shapiro Wilk, Anderson-Darling and Jarque-Bera test. The normal distribution tests were performed in the Past 3 program \[[@pone.0232351.ref069]\] (<https://folk.uio.no/ohammer/past/>).

Normally distributed data from qRT-PCR were analysed using Student's T-test while the not-normally distributed data was analysed using Mann-Whitney U test. Logistic regression analysis was used to describe the dependency of the dependent outcome, the diagnosis in this case, and was performed on each miRNA separately. In addition, a logistic regression was performed on multiple sets of variables (miRNAs) in order to predict the diagnosis (ASD or DD). The logistic regression was calculated with Xlstat add-on within the Microsoft Office Excel program.

A Receiver Operating Characteristic (ROC) curve of the created prediction models was also calculated as it can provide an unbiased assessment of the overall model performance. Therefore, the ROC can be used for evaluating the diagnostic power of miRNAs. In order to further support the results found using the logistic regression a multivariate linear regression of Partial Least Squares-Discriminant analysis (PLS-DA) was calculated. The PLS-DA calculates the multivariate linear combinations from the 14 miRNAs of interest that are best predictors of the class of interest. PLS-DA was also calculated with the Xlstat add-on. For all models, a cross validation was performed by randomly dividing the dataset into a training and validation set. The size of training and validation sets were determined based on the sample size being analysed (approximately 10%). Multiple iterations of the models were performed to ensure randomness within the models. Furthermore, parameters chosen were the default parameters (0.5 prediction threshold) and the sporadic missing data was predicted using the nearest neighbour method approach.

Results {#sec006}
=======

Out of 14 analysed miRNAs, 6 were differentially expressed between typically developing children and children with some type of developmental disorder (which includes ASD). These were miR-7-5p, miR-23a-3p, miR-32-5p, miR-140-3p, miR-628-5p and miR-2467-5p. Two miRNAs were up-regulated (miR-7-5p and miR-2467-5p), while 4 were down-regulated (miR-23a-3p, miR-32-5p, miR-140-3p and miR-628-5p) ([Table 3](#pone.0232351.t003){ref-type="table"}). MiRNA with largest difference in average expression was miR-32-5p, followed by miR-23a-3p. Normalized Ct value data for each individual miRNA within the three cohorts was presented in a Box Plot and Jitter graph ([Fig 1](#pone.0232351.g001){ref-type="fig"}). Details on the percentage of obtained Ct values for every cohort and for each individual miRNA can be seen in [S1 Table](#pone.0232351.s001){ref-type="supplementary-material"}.

![Box and jitter graph of the normalized Ct values for each miRNA within the three analysed cohorts (TD, ASD and non-ASD DD).](pone.0232351.g001){#pone.0232351.g001}

10.1371/journal.pone.0232351.t003

###### Differentially expressed miRNAs within the analysed cohorts and their directional expression changes relative to the control group.
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  Cohorts          Expression pattern (p-value)
  ---------------- ------------------------------
  **DD**           
  miR-7-5p         Up-regulated (0.0361)
  miR-23a-3p       Down-regulated (0.0001)
  miR-32-5p        Down-regulated (0.0001)
  miR-140-3p       Down-regulated (0.0067)
  miR-628-5p       Down-regulated (0.0001)
  miR-2467-5p      Up-regulated (0.0499)
  **ASD**          
  miR-7-5p         Up-regulated (0.0172)
  miR-23a-3p       Down-regulated (0.0001)
  miR-32-5p        Down-regulated (0.0001)
  miR-140-3p       Down-regulated (0.0053)
  miR-628-5p       Down-regulated (0.0005)
  **Non-ASD DD**   
  miR-23a-3p       Down-regulated (0.0033)
  miR-32-5p        Down-regulated (0.0102)
  miR-628-5p       Down-regulated (0.0135)
  miR-2467-5p      Up-regulated (0.0057)

Out of 14 miRNAs, analysed in ASD samples, 5 were differentially expressed according to Mann Whitney U test. Four miRNAs were down-regulated while one was up-regulated ([Table 3](#pone.0232351.t003){ref-type="table"}). Down-regulated miRNAs within ASD group were miR-23a-3p, miR-32-5p, miR-628-5p and miR-140-3p, while significantly up-regulated was miR-7-5p. MiRNA with the largest difference in average expression was miR-32-5p, followed by miR-23a-3p. Differentially expressed miRNAs within non-ASD group, when compared to the control group, were miR-23a-3p, miR-32-5p, mir-628-5p and miR-2467-5p. MiR-2467-5p was upregulated while the other 3 miRNAs were all down-regulated ([Table 3](#pone.0232351.t003){ref-type="table"}).

Logistic regression performed on individual miRNAs between TD and children with ASD, as a subgroup of DD, has shown that the best performing miRNAs in differentiating between these groups were miR-32-5p (-2Log(Likelihood): 7.363; p-value: 0.007) and miR-23a-3p (-2Log(Likelihood): 5.406; p-value: 0.020). Following these two miRNAs, the best performing were miR-7-5p, miR-218-5p, miR-27a-3p and miR-628-5p, although their GoF statistics were not significant. When the values of ROC AUC were taken into consideration the best performing miRNAs were miR-23-3p, miR-32-5p and miR-7-5p.

Logistic regression was also performed on individual miRNAs between typically developing children and children with some type of developmental disorder (this cohort included ASD and non-ASD DD groups) and the best performing individual miRNA in classifying between these groups were miR-32-5p (-2Log (Likelihood): 11.208; p-value: 0.001) followed by miR-23a-3p (-2Log(Likelihood): 9.507; p-value: 0.002). MiR-628-5p, miR-7-5p and miR-27a-3p have also shown a very good performance in classifying between TD and DD children. Out of the latter 3 miRNAs, only miR-628-5p had significant -2Log(Likelihood) statistic (-2Log (Likelihood): 6.247; p-value: 0.012). When the values of ROC AUC were taken into consideration, miR-32-5p and miR-23a-3p again had the best performance. MiR-628-5p also had a relatively high ROC AUC (0.696).

In the logistic regression on individual miRNAs between non-ASD DD group and typically developing children only one, miR-32-5p, had significant -2Log(Likelihood) statistic of 9.301 with a p-value of 0.002. MiRNAs close to having a statistically significant GoF statistics were miR-23a-3p (-2Log(Likelihood): 3.127; p-value: 0.067) and miR-3529-3p (-2Log(Likelihood): 2.915; p-value: 0.088). For further details please refer to [S8](#pone.0232351.s008){ref-type="supplementary-material"}--[S11](#pone.0232351.s011){ref-type="supplementary-material"} Tables.

PLS-DA performed on TD children and children with ASD had shown that the most contributing miRNAs in creating the PLS-DA were miR-23a-3p, miR-32-5p, miR-7-5p, miR-27a-3p, miR-628-5p and miR-140-3p, in order. The sensitivity and specificity for this PLS-DA model were 64% and 88.57% respectively. The total accuracy was 78.33%. The AUC for the ROC of the PLS-DA model was 0.920. For the PLS-DA performed on TD and DD cohorts, miRNAs with the most significant contribution to PLS-DA model were (from most to least significant): miR-23a-3p, miR-7-5p, miR-32-5p, miR-27a-3p, miR-628-5p, miR-140-3p and miR-2467-5p. The overall prediction model for the PLS-DA had a 36% specificity, 86.27% sensitivity and a total accuracy of 69.74%. For the calculated ROC Curve the AUC was 0.793. MiRNAs with the highest VIP scores were miR-23a-3p, miR-7-5p and miR-32-5p. The PLS-DA on non-ASD DD group and typically developing children had shown that the most contributing miRNAs in creating this PLS-DA prediction model were miR-32-5p, miR-23a-3p, miR-628-5p, miR-7-5p. This PLS-DA model had 88% specificity and 64.29% specificity. The total accuracy and ROC AUC were 79.49% and 0.749, respectively ([S6](#pone.0232351.s006){ref-type="supplementary-material"} and [S7](#pone.0232351.s007){ref-type="supplementary-material"} Tables).

Overfitting was suspected on the logistic regression model of 14 miRNAs which predicted ASD children from TD. That model had maximum specificity and sensitivity for the training set and 66.67% specificity and 100% sensitivity for the validation set. Hence, a more reliable model was created which included 5 miRNAs (best performing in the previously mentioned model) (miR-7-5p, miR-23a-3p, miR-27a-3p, miR-140-3p and miR-2467-5p). The -2Log(Likelihood) value of the model was 40.237 with a p-value of \<0.0001. Specificity was 90.00%, sensitivity was 90.32% ([Table 4](#pone.0232351.t004){ref-type="table"}) and the ROC AUC of the model was 0.952. The validation set had an accuracy of 90%.

10.1371/journal.pone.0232351.t004

###### Performance of the logistic regression prediction models (includes sensitivity, specificity and accuracy along with their confidence intervals) which have shown statistically significant ability of differentiating between the analysed groups.
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  Model             Sensitivity (95% CI)      Specificity (95% CI)      Accuracy (95% CI)
  ----------------- ------------------------- ------------------------- -------------------------
  TD-DD             86.36% (65.09%--97.09%)   93.18% (81.34%--98.57%)   90.91% (81.26%--96.59%)
  TD-ASD            90.32% (63.66%--96.95%)   90% (77.93%--99.18%)      90.2% (78.59%--96.74%)
  TD---non-ASD DD   75% (66.27%--95.81%)      92% (57.19%--98.22%)      85.37% (70.83%--94.43%)

\*CI---Confidence Interval.

The logistic regression on the full set of variables performed on typically developing children and children with any type of developmental disorder had a maximum specificity and sensitivity for the training set and 50% specificity and 100% sensitivity for the validation set. Since overfitting was suspected, a model with 7 miRNAs (best performing in the previously mentioned model) (miR-7-5p, miR-23a-3p, miR-27a-3p, miR-32-5p, miR-140-3p, miR-628-5p and miR-2467-5p) was created. The -2Log(Likelihood) for this model was 62.805 with a p-value of \<0,0001. The specificity and sensitivity values were 86.36% and 93.18%, respectively ([Table 4](#pone.0232351.t004){ref-type="table"}). The ROC AUC of the model was 0.983. The validation set had an accuracy of 90%. As the logistic regression model on non-ASD DD and TD children also had maximum accuracy, overfitting had to be taken into consideration. Hence, the best performing model on reduced number of miRNAs was based on 5 miRNAs (best performing in the previously mentioned model) (miR-7-5p, miR-23a-3p, miR-32-5p, miR-140-3p, miR-3529-3p). The -2Log(Likelihood) value of the model was 30.013 with a p-value of \<0.0001. Specificity was 92.00%, sensitivity was 75.00% ([Table 4](#pone.0232351.t004){ref-type="table"}) and the ROC AUC of the model was 0.940. The validation set was too small (5 samples) for meaningful conclusions. However, within randomly chosen 5 validation samples 100% accuracy in their classification was observed. Details on the mentioned models can be seen in [Fig 2](#pone.0232351.g002){ref-type="fig"}. Furthermore, we have performed a power analysis (where the number of final sample sizes for each miRNA or test can be seen) on all models and individual miRNAs which have shown statistically significant ability in differentiating between cohorts ([S2](#pone.0232351.s002){ref-type="supplementary-material"}--[S5](#pone.0232351.s005){ref-type="supplementary-material"} Tables).

![Comparison of the 4 logistic regression models.\
Models A, B and C have shown statistically significant differentiation between groups. Presented are ROC AUC, sensitivity, specificity and accuracy values of the models.](pone.0232351.g002){#pone.0232351.g002}

Discussion {#sec007}
==========

We have analysed expression of 14 miRNAs in saliva samples of children with DD including ASD and TD. Six miRNAs were found to be differentially expressed in children with DD. Furthermore, when samples of children with ASD were analysed, 5 miRNAs were found to be differentially expressed. All 5 miRNAs from ASD analysis were found within the group of 6 miRNAs differentially expressed in children with DD. Only miR-2467-5p was not differentially expressed among children with ASD. We have found that this particular miRNA had significant difference in abundance in ASD when compared to other DD samples. Out of differentially expressed miRNAs among children with ASD, with the exception of miR-140-3p and miR-628-5p, all had concordant expression patterns to a previously reported study \[[@pone.0232351.ref053]\]. In our study miR-140-3p and miR-628-5p were down-regulated, while they were up-regulated in the mentioned study.

Using the most optimal logistic regression model, we were able to distinguish between ASD and TD children. We have found 5 miRNAs as potential biomarkers. Out of these 5 miRNAs, 3 were differentially expressed within the ASD cohort. All 5 miRNAs have shown good chi-square statistics within the logistic regression model which utilized all 14 miRNAs analysed in this study. The accuracy of 5-miRNA logistic regression model training set was 90.20%, while the validation set had a 90% accuracy. The logistic regression performed only on differentially expressed miRNAs between ASD and TD has shown poorer results than the previously discussed model. Moreover, the best logistic regression model which attempted to distinguish between DD and TD children included 7 miRNAs as variables (miRNAs). Six of these were differentially expressed among children with DD while one, which was not differentially expressed (miR-27-3p), has shown a relatively large VIP value within the PLS-DA. This model had a total accuracy of 90.91% in the training set and 90% accuracy within the validation set. The best performing logistic regression model, attempted to differentiate between non-ASD DD and TD cohorts, included 5 variables. Two of the five miRNAs were differentially expressed, while 3 have performed very well in the model which included the complete set of 14 miRNAs. In this study cross validation was used for validating the trained models. In order to obtain more reliable validation results an independent sample cohort for validation would be suitable.

The three main prediction models (distinguishing children with ASD, any type of DD or non-ASD developmental disorder from TD) have all shown results with significant GoF statistics and satisfactory accuracy. The model used to differentiate between children with DD and TD had the best performance followed by the model on ASD and TD children. Finally, the model which attempted to differentiate between non-ASD DD and TD children had the poorest performance out of the 3 models. The results obtained from the discussed logistic regressions models were fully supported by the PLS-DA performed on the same groups.

In this study we have found that, individually, the best miRNAs for differentiating between children with ASD or even DD from TD were miR-23-3p and miR-32-5p. The same was true when differentiating non-ASD cohort from TD. It has been found that miR-23a-3p functions cooperatively with miR-27a-3p to regulate cell proliferation and differentiation \[[@pone.0232351.ref070]\]. Furthermore, miR-23a-3p and miR-27a-3p were also dysregulated in a number of human diseases and disorders, including ASD \[[@pone.0232351.ref049], [@pone.0232351.ref053], [@pone.0232351.ref071]\]. Levels of miR-23a-3p also fluctuated in response to CNS injuries such as cerebral ischemia \[[@pone.0232351.ref072]\] or temporal epilepsy \[[@pone.0232351.ref073]\], both of which are associated with ASD \[[@pone.0232351.ref074]\]. MiR-23a-3p was also found to be dysregulated in 3 other studies \[[@pone.0232351.ref042], [@pone.0232351.ref045], [@pone.0232351.ref049]\]. MiR-32-5p is believed to be involved in certain processes which promote cell proliferation, migration and suppresses apoptosis in breast cancer while inhibiting proliferation and invasion in gastric cancer cell lines \[[@pone.0232351.ref075], [@pone.0232351.ref076]\].

Studies on biomarkers, as potential diagnostic tools for ASD, have also developed successful prediction models. There have been numerous studies on differentially expressed miRNAs within ASD children including analysis of their suitability as biomarkers \[[@pone.0232351.ref051]\]. MiR-23a-3p analysed by Hicks et al., 2016 \[[@pone.0232351.ref053]\], Sarachana et al., 2010 \[[@pone.0232351.ref055]\] has been shown to be significantly down-regulated. Moreover, when it comes to individual performance of miRNAs, differentially expressed miRNAs in this study had a lower prediction power than in Hicks et al., 2016 \[[@pone.0232351.ref053]\] or Vasu et al., in 2014 \[[@pone.0232351.ref049]\]. Prediction models utilizing multiple miRNAs or other types of RNAs as biomarkers for ASD have also been studied and overall show better prediction capabilities. One such example is the study which utilized 14 miRNAs and obtained 95.6% specificity, 100% sensitivity and an area under the ROC curve of 0.974 \[[@pone.0232351.ref053]\]. In this study, the best individually performing miRNAs were miR-335-3p and miR-30-5p, whereas in our study the best performing miRNAs were miR-23a-3p and miR-32-5p.

In addition, another study \[[@pone.0232351.ref058]\] used a combination of RNA molecules (1 snoRNA, 8 piRNAs, 4 precursor miRNAs, 7 mature miRNAs and 12 microbial taxa) and reported 78.3% specificity, 79.9% sensitivity and an area under the ROC curve of 0.868.

When analysing miRNAs in ASD individuals relatively small percentage of differentially expressed miRNAs overlap between studies. A total of 3 miRNAs showed consistent dysregulation in 3 or more studies \[[@pone.0232351.ref077]\]. These differences in obtained differentially expressed miRNAs, also applicable to our study, can be explained by the effect of different factors such as age, ethnicity, ASD heterogeneity, different RNA collection devices, RNA quantification and analysis and miRNA role in development. It has been shown that the overall ASD prevalence is higher in males then in females, \[[@pone.0232351.ref078], [@pone.0232351.ref079]\] as was observed in our study. One potential explanation \[[@pone.0232351.ref080]\] is the female genome resistance and the fact that more severe symptoms are usually required in order for females to be detected \[[@pone.0232351.ref078]--[@pone.0232351.ref081]\]. As such biases are present across biomarker ASD studies \[[@pone.0232351.ref043], [@pone.0232351.ref058]\], more research would have to be performed in order to determine the effect gender has, if at all, on miRNA expression. The referenced study \[[@pone.0232351.ref053]\] involved children 5 to 14 years of age. In our study, on the other hand, we involved children ([Table 2](#pone.0232351.t002){ref-type="table"}) 3 to 8 years of age in an attempt to test children as early as possible or as close as possible to ASD diagnosis in order to evaluate the combination of performed tests (clinical and biomarker) and their accuracy in diagnosing ASD. Furthermore, a recent review reported no differences in prevalence across geographic regions or variability based on ethnicity or socioeconomic factors; however, they did add that the lack of comprehensive datasets from low-income countries impacts the ability to detect these effects \[[@pone.0232351.ref016]\]. Therefore, testing miRNAs as biomarkers of ASD in different ethnic groups including those from LMIC's is absolutely needed. We have found correlation with compared studies as well; however, further model improvement has to be performed on much larger population. In addition, Hicks' study targeted children with "high functioning" ASD (average ADOS-II score = 10.6 ± 4.1), whereas our study included ASD and DD children classified by CARS-II as Mild-to-Moderate and Severe ASD Symptoms category for ASD and Minimal-to-No Symptoms of ASD CARS-II category for non-ASD DD children. Because salivary miRNA expression is associated with levels of ASD symptoms, it is likely that this also contributes to observed differences in miRNA expression. In order to validate used scale (CARS II) we have randomly selected 26/55 (47%) children for clinical evaluation by child psychiatrist. This validation showed 100% concordance between CARS II and child psychiatrists' evaluation and confirmed the reliability of the used scale. However, the fact that we performed clinical evaluation on approximately 50% of children may represent a limiting factor on such a validation. In our study we used collection devices (Samplifybio saliva collection kit) different from the referred study \[[@pone.0232351.ref053]\]. The RNA preservation liquid between the two devices may have, additionally, contributed to miRNA expression differences. Our method of choice was RT-PCR as a relatively cheap and available method in most medical labs in LMIC. Therefore, we expected differences in expression and detection obtained by RT-PCR when compared to a more robust sequencing method used by Hicks et al. 2016. Nonetheless, models utilizing salivary miRNA and detection with RT-PCR can be used to differentiate children with ASD from typically developing or non-ASD DD children \[[@pone.0232351.ref030]\]. However, in order to improve their specificity and make them applicable in clinical setting, the proposed models have to be tested on a larger population and potentially, as suggested by Hicks et al. 2018, by employing a multi-"omic" approach using additional RNA families.

Furthermore, as miRNA expression is a dynamic process which changes throughout development we have to consider its effect on miRNA expression differentiation \[[@pone.0232351.ref043]\] However, it has been shown that miRNAs are essential for survival and differentiation of newborn neurons but not for expansion of neural progenitors during early neurogenesis in the mouse embryonic neocortex \[[@pone.0232351.ref043]\]. Although there is a chance that some of the found differences are affected by the miRNA involvement in neural development, majority of our findings are on children of average age of 5 and same ethnicity. Looking at the younger children such as infants and toddlers may shed more light in the future on the potential differences in miRNA expression due to developmental processes better.

Finally, in an earlier *in silico* study \[[@pone.0232351.ref082]\] target mRNAs of the same 14 miRNAs were analysed. Genes reported to be targeted by all 14 miRNAs and have more than 7 predicted target sites were: MAPK10, KCNMA1 and DST. The number of predicted sites was used as an indirect measure of how correlated an mRNA was with the miRNA in question. In the same study, genes reported to be targeted by 13 miRNAs and have more than 7 predicted target sites were reported. Those genes were ZBTB20, GAS7, NTRK2 and SCN2A. It is thought that most of these genes are related to neural processes and are directly or indirectly related to ASD. According to Hicks et al., 2016 \[[@pone.0232351.ref049]\] the notable ASD-associated mRNA targets of these 14 miRNAs are Fragile X Mental Retardation (FMR1) and Forkhead Box Protein P2 (FOXP2). Those mRNAs predicted to have a function most relevant to ASD were mapped to the Neuron Projection and Axon Projection subnodes.

Conclusion {#sec008}
==========

This study has shown that miRNAs can be considered as biomarkers for ASD diagnosis and could be used to identify children with ASD at a very early stage of life. We performed a transdisciplinary cooperation in order to define the most optimal and accurate approach in identifying children with developmental disorders, including ASD, in low to mid income countries such as Bosnia and Herzegovina. We have done this by utilizing a combination of molecular analysis, based on miRNAs as biomarkers, and screening methods such as EDUS-DBS, CARS II and clinical analysis. Our molecular analysis was based on a panel of 14 miRNAs previously shown as good biomarkers for ASD. We have found that even subsets of this panel of miRNAs have the potential to be used as diagnostic biomarkers for ASD and/or DD. Out of 14 miRNAs analysed in this study, miR-32-5p, miR-23a-3p and miR-7-5p, have been found as good candidates for biomarkers in differentiating children with ASD from typically developing children. The best miRNAs for differentiating between children with any type of developmental disorder and typically developing children were miR-23a-3p, miR-32-5p and miR-628-5p. As previously suggested, a good step towards implementing miRNAs as ASD or DD biomarkers would be large scale validation study with multi-"omics" approach along with currently employed screening tests. This would lead to an optimized biomarker diagnostic tool that complements current screening tests.

Supporting information {#sec009}
======================
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Reviewer \#1: 1) It is unclear how the 14 miRNAs were selected. It seems to be based on reference 49 (A comparative review of microRNA expression patterns in autism spectrum disorder. Frontiers in psychiatry. 2016); however, I do not see much overlap with the 27 miRNAs discussed in that paper.

2\) "The validation set" was mentioned, but it is unclear what that is.

Reviewer \#2: Overall, this is an interesting manuscript which interrogates an emerging biomarker family in a clinical disorder with a great need for an objective, biologic diagnostic aid.

The novelty of the manuscript lies in its unique ethno-geographic cohort, and the potential to confirm previously-published, non-invasive biomarkers in that cohort. The authors have done a thorough job providing clinical characteristics of the participants, and the statistical approach appears sound.

My main concern is regarding the interpretation of the results, and the way the discussion frames them (in the context of the existing literature). The authors are missing a key citation, which involves the largest study of saliva microRNA in children with autism (PMID: 30926572). This study showed that saliva microRNA alone does not provide sufficient accuracy for differentiating children with ASD from peers with DD or TD. This is why additional studies (e.g. citation 54) have moved to poly-omic analysis of both microRNA and other human and microbial RNAs. For this reason, a study of \<100 children is not really a validation study - especially since the authors have used different saliva collection kits, different RNA extraction techniques, and different RNA quantification protocols. The discussion does not include any mention of these factors. There is also no discussion of the study\'s limitations.

Here are a few additional specific observations/suggestions:

The intro would benefit from a discussion of the advantages to saliva relative to blood collection.

This study does not show that microRNAs can be used as early as birth for ASD diagnosis. There are studies to show this type of test is not even a priority for parents of children with ASD (PMID: 30903561).

I worry that the sample size (n=25 for controls) does not support separate training/test sets. A power analysis would be useful here.

Table 1 needs to compare sex/age across groups (were there differences?). Also, details about diet, oral hygiene, and oral meds would help with interpretation of the findings.

Were any participants excluded for inability to expectorate?

Please provide data on RNA quality and concentrations. Box plots for miRNA expression across groups is necessary.

Were all miRNAs detectable? In what % of participants? What were the Ct values?

Line 381-2: I would suggest a thorough discussion of why the results might differ across saliva microRNA studies: sex, age, race, ethnicity, saliva collection devices, RNA extraction devices, RNA quant approaches, composition of ASD/DD groups, severity of ASD group, small sample size of the current study (relative to newer studies in the field) could all be factors that led to differences across studies.

If I am interpreting the text correctly, 47% of children with ASD received a clinical evaluation. This is a limitation that should be discussed.

Reviewer \#3: Sehovic et al. present work detailing the use of miRNA in saliva to distinguish between children with developmental disabilities and autism against typically developing children. Using qPCR assay the group evaluates differentially expressed miRNA and from this subset with logistic regression to find the most predictive miRNA. Further they use PLS-DA in order to work with the full set of miRNA to determine optimal sets of miRNA that are best predictive (the study draws its 14 candidate miRNA from previously published work from Hicks et al.). After iterations of modelling, the group demonstrates strong performance with sets of 5, 7, and 5 miRNA for distinguishing ASD from TD, any DD from TD, and non-ASD DD from TD, while the ability to distinguish ASD from other DD was prone to false positives.

While the idea of using salivary miRNA is not new and the authors are very clear they are drawing from sets of miRNA already implicated in earlier work, this study is important as it confirms their strength as diagnostic makers for ASD/DD. Furthermore, the use of an understudied cohort is valuable to show that these markers have widespread utility, and as the authors point out, provide accessibility in low and mid-income countries to reach necessary individuals for early intervention. Also, the paper shows the importance of looking at panels of markers rather than individual markers. Overall, the paper is well written, but would be strengthened with further presentation of the data in the paper.

While all results are displayed in the text it is difficult to gauge which are common and how great changes are by comparing sections of text. Unfortunately, the naming of miRNA does not lend itself well to easy distinction at a glance. The paper would be aided by separating DE miRNA into tables that include directional fold change differences and p-values. I realize this adds cost of redundancy, but that is offset by the value of the clarity. Tables for DE results and then for prediction results of both single logistic and PLS-DA results would be useful. I believe a heatmap showing the specific DE miRNA across all the samples and labelled with the category would be useful to see how consistent the results are across the cohort. As it stands, the buildup to the lone figure is somewhat lost, but important to understand the strength of the marker set used and the diversity of the sample cohort.

There seems to also be some clarification needed in certain areas. For instance, it was unclear why only 26 children have clinical opinion from the child psychologist and initial thoughts were that the rest were deemed non-ASD or non-DD. It is clarified that only a subset of these children were evaluated, but the message was that of agreement between CARS-II and the clinical assessment. Perhaps the table can call that section Concordance between Child Psychiatrist and CARS-II or have that added to be more clear?

It is not clear how samples were separated into training and validation. There is a line at the end of the results section that mentions 5 samples in the validation being too small for meaningful conclusions. Is that the number for all or just the non-ASD DD vs TD? The number in each set should be provided to understand the design and relevance of the training and validation sets.

Please ensure all miRNA names are miR- and not miRNA-. Also watch for some uses of mir-.

Lines 388-389 -- The statement "Other notable genes were CACNA1C and DST." is unclear. DST is already mentioned on line 385. Four target genes for the 13 miRNA with 7 target sites are given. What is notable and different about these two genes? What is different about DST mentioned here compared to line 385?

Reviewer \#4: Sehovic et al. evaluated whether miRNA can be used as biomarkers in children with suspected developmental disorders within Bosnian-Herzegovinian population. They analyzed 14 selected miRNAs and identified 6 were differentially expressed between typically developing children and children with developmental disorder. Further logistic regression identified 5 as potential biomarkers for Autism spectrum disorder detection.
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4\. Please provide the reasoning or support to use z-score of 1.5 as an outlier threshold, which seems quite small.

5\. Line 213 reads, "used to describe the dependency of the dependent outcome, the diagnosis in this case,.." please clarify the outcome, ASD vs DD, without considering TD? If so, it implies that the analysis of interest only focus on ASD and DD sample. Then it would be useful to present Table 2 stratified by diagnosis status rather than pooling them together. If not, then please be clear about your modeling.

6\. Lines 282 and 283 talk about training set and the validation set. However, it doesn't mention anything about different dataset in the statistical analysis section. Please provide the detail and define your training and testing datasets!
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Dear Reviewers,

Thank you so much for your time and such thorough comments and suggestions. All of your suggestions and comments have been addressed and the manuscript has been updated accordingly. Answers to your comments and how they have been addressed, in detail, please find below.

Once more thank you.

Sincerely,

Authors

REVIEWER 1

1\. It is unclear how the 14 miRNAs were selected. It seems to be based on reference 49 (A comparative review of microRNA expression patterns in autism spectrum disorder. Frontiers in psychiatry. 2016); however, I do not see much overlap with the 27 miRNAs discussed in that paper.

We have selected the 14 miRNAs based on their performance in Hicks et al., 2016.

2\. The validation set" was mentioned, but it is unclear what that is.

Our validation set was made up of 10% of randomly selected samples from the overall analysed cohort.

REVIEWER 2

1\. The authors are missing a key citation, which involves the largest study of saliva microRNA in children with autism (PMID: 30926572).

As suggested we have included the key citation PMID: 30926572 within the discussion section (line: 100, 460).

2\. This is why additional studies (e.g. citation 54) have moved to poly-omic analysis of both microRNA and other human and microbial RNAs. For this reason, a study of \<100 children is not really a validation study - especially since the authors have used different saliva collection kits, different RNA extraction techniques, and different RNA quantification protocols. The discussion does not include any mention of these factors. There is also no discussion of the study\'s limitations.

Poliomic analysis has been addressed and included in discussion. We agree that this is not a validation study, it is an additional test for assessment of children with developmental disorders and have made contextual changes accordingly (line: 37)

Study limitations have been addressed, (line: 425)

3\. The intro would benefit from a discussion of the advantages to saliva relative to blood collection.

As suggested the advantages of salivary relative to blood collection were discussed in the introduction (line: 94)

4\. This study does not show that microRNAs can be used as early as birth for ASD diagnosis. There are studies to show this type of test is not even a priority for parents of children with ASD (PMID: 30903561).

Based on the suggestion we have adjusted the utility of miRNAs as diagnostic tools as early as birth.

5\. I worry that the sample size (n=25 for controls) does not support separate training/test sets. A power analysis would be useful here.

Power analysis has been performed and is included within the Supplementary Material 2.

6\. Table 1 needs to compare sex/age across groups (were there differences?). Also, details about diet, oral hygiene, and oral meds would help with interpretation of the findings.

We have adjusted table 1 according to the suggestions for the control group and we have added the suggested information (sex/age) regarding DD children in Table 2. We do not have information regarding diet, oral hygiene and oral meds.

7\. Were any participants excluded for inability to expectorate

There was one sample mentioned in Materials and Methods section (line: 150)

8\. Please provide data on RNA quality and concentrations. Box plots for miRNA expression across groups is necessary.

Data on RNA quality and concentrations is provided to the reviewer attached as an excel file ("Samples ASD") and the box plots for miRNA expression across groups has been added as a figure in the manuscript (Figure 1).

9\. Were all miRNAs detectable? In what % of participants? What were the Ct values?

Data regarding the percentages of detected miRNAs have been added and can be found in Supplementary file 1. Raw Ct value data has been attached as an excel file ("Ct value and normalization")

10\. Line 381-2: I would suggest a thorough discussion of why the results might differ across saliva microRNA studies: sex, age, race, ethnicity, saliva collection devices, RNA extraction devices, RNA quant approaches, composition of ASD/DD groups, severity of ASD group, small sample size of the current study (relative to newer studies in the field) could all be factors that led to differences across studies.

According the suggestion we have addressed the mentioned differences in the discussion (427)

11\. If I am interpreting the text correctly, 47% of children with ASD received a clinical evaluation. This is a limitation that should be discussed.

The mentioned limitation has been addressed in the discussion (line: 452)

REVIEWER 3

1\. Overall, the paper is well written, but would be strengthened with further presentation of the data in the paper.

As suggested by the reviewer, additional data was added in the paper through Figure 1, Table 3 and Supplementary Tables 1 to 11 a and 2.

2\. While all results are displayed in the text it is difficult to gauge which are common and how great changes are by comparing sections of text. Unfortunately, the naming of miRNA does not lend itself well to easy distinction at a glance. The paper would be aided by separating DE miRNA into tables that include directional fold change differences and p-values. I realize this adds cost of redundancy, but that is offset by the value of the clarity. Tables for DE results and then for prediction results of both single logistic and PLS-DA results would be useful. I believe a heatmap showing the specific DE miRNA across all the samples and labelled with the category would be useful to see how consistent the results are across the cohort. As it stands, the buildup to the lone figure is somewhat lost, but important to understand the strength of the marker set used and the diversity of the sample cohort.

The naming of miRNAs was addressed. Differentially expressed miRNAs with directional fold changes and p-values were included in Table 3. Regarding the suggested tables for individual miRNA LR performance and PLS-DA performance we have decided that it would be more suitable to add such tables as supplements to text in order to preserve the consistency of data presented in the text.

After constructing boxplots proposed by Reviewer 2 and heatmaps by Reviewer 3 for visualizing the expression patterns of individual miRNAs within studies groups, we have decided that boxplots visually offer more clarity and information.

Table showing differential expression is added

3\. There seems to also be some clarification needed in certain areas. For instance, it was unclear why only 26 children have clinical opinion from the child psychologist and initial thoughts were that the rest were deemed non-ASD or non-DD. It is clarified that only a subset of these children were evaluated, but the message was that of agreement between CARS-II and the clinical assessment. Perhaps the table can call that section Concordance between Child Psychiatrist and CARS-II or have that added to be more clear?

Clinical evaluation and the mentioned issues by the reviewer were thoroughly addressed in materials and methods and discussion sections of the manuscript. Concordance between child psychiatrist and CARS 2 has been added in Table 2.

4\. It is not clear how samples were separated into training and validation. There is a line at the end of the results section that mentions 5 samples in the validation being too small for meaningful conclusions. Is that the number for all or just the non-ASD DD vs TD? The number in each set should be provided to understand the design and relevance of the training and validation sets.

The used program randomly separates the training and validation sets, multiple iterations were performed, and the results did not differ significantly. A smaller validation subset was selected only for non-ASD DD because their sample size was smaller than others. Based on your suggestion the whole process of validation has been more thoroughly explained within the materials and methods section of the manuscript.

5\. Please ensure all miRNA names are miR- and not miRNA-. Also watch for some uses of mir-.

Based on your suggestion the naming of miRNAs has been addressed.

6\. Lines 388-389 -- The statement "Other notable genes were CACNA1C and DST." is unclear. DST is already mentioned on line 385. Four target genes for the 13 miRNA with 7 target sites are given. What is notable and different about these two genes? What is different about DST mentioned here compared to line 385?

We agree with your suggestion and have removed lines 388-389 as they do not provide novel conclusions.

REVIEWER 4

1\. The abbreviation should be spelled out for the first time use, e.g. What's TD in abstract?

Based on your suggestion the abbreviation has been addressed.

2\. Please clarify how 80 participants were sampled. Are they all the patients collected in a certain period of time?

The issues with sampling addressed by the reviewer have been addressed in Materials and Methods section of the manuscript (Paragraph 2)

3\. 26 children were selected for clinical observations. How were these children selected? Also, how were their characteristics compared to the remaining children?

Clinical evaluation and the mentioned issues by the reviewer were thoroughly addressed in materials and methods and discussion sections of the manuscript. Concordance between child psychiatrist and CARS 2 has been added in Table 2.

4\. Please provide the reasoning or support to use z-score of 1.5 as an outlier threshold, which seems quite small. ?

The reasoning behind using 1.5 Z score as the outlier threshold has been explained in materials and methods section (line: 237)

5\. Line 213 reads, "used to describe the dependency of the dependent outcome, the diagnosis in this case,.." please clarify the outcome, ASD vs DD, without considering TD? If so, it implies that the analysis of interest only focus on ASD and DD sample. Then it would be useful to present Table 2 stratified by diagnosis status rather than pooling them together. If not, then please be clear about your modeling.

According to your remark we stratified Table 2 based on diagnosis status.

6\. Lines 282 and 283 talk about training set and the validation set. However, it doesn't mention anything about different dataset in the statistical analysis section. Please provide the detail and define your training and testing datasets!

Random separation of the training and validation sets was done and multiple iterations were performed. A smaller validation subset was selected only for non-ASD DD because their sample size was smaller than others. Based on your suggestion the whole process of validation has been more thoroughly explained within the materials and methods section of the manuscript.
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PLOS ONE

Dear Dr. Hajdarpasic,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Apr 03 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Lucia Billeci

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

Reviewer \#3: (No Response)

Reviewer \#4: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: No

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: (No Response)

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: (No Response)

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: (No Response)

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: (No Response)

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: 1) "We have selected the 14 miRNAs based on their performance in Hicks et al., 2016."--- It is still unclear how the 14 miRNAs were selected. The main point of Hicks et al's paper is 27 miRNAs with overlap across ASD studies; however, I do not see much overlap with the 27 miRNAs discussed in that paper.

2\) It seems the authors are not even familiar with the statistical techniques you used in the manuscript. Cross validation (CV) was used because there is no replication study; however, this key word was not even clearly written.

Reviewer \#2: The authors have adequately addressed each of my comments.

The manuscript is suitable for publication.

Reviewer \#3: Sehovic and colleagues have made important additions, changes and clarifications to their manuscript describing the study of miRNA to distinguish ASD and DD from typically developing children in B-H.

Additional data/results help support the evaluation of the miRNA panel and determination of optimally predictive subsets used in this study. Limitations of the study are generally made clear, so that overall context is better understood. However, it seems that there may be confusion related to the training and validation sets, or at least the terminology used, which still may need clarification.

Specifically, it appears as though the entire cohort was used as training less \~10% held back for validation. This was repeated through 'multiple iterations' (line 258) using the software. I would contend that this would generally be recognized as cross-validation and the paper should be clear at some point that validation is referring to cross validation, which is different from a fully withheld and independent validation set. Similar, a limitation outlining the need for a fully independent sample cohort for validation should be included.

The change of using the term spit to expectorant/expectorate is improper as it implies collection of phlegm and mucus from the lungs or throat rather than saliva (which it is meant to be reflected). This should be changed back to the previous wording (lines 107, 152).

Other corrections are required in the tables in S6, S8-S11 with respect to formatting and decimals.

Reviewer \#4: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

Reviewer \#4: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 1

2 Apr 2020

Dear Reviewers,

Thank you so much for your time and such thorough comments and suggestions. All of your suggestions and comments have been addressed and the manuscript has been updated accordingly. Answers to your comments and how they have been addressed, in detail, please find below.

Once more thank you.

Sincerely,

Authors

REWIER 1

1\) "We have selected the 14 miRNAs based on their performance in Hicks et al., 2016."--- It is still unclear how the 14 miRNAs were selected. The main point of Hicks et al's paper is 27 miRNAs with overlap across ASD studies; however, I do not see much overlap with the 27 miRNAs discussed in that paper.

There are 2 articles published in 2016 by Hicks and his colleagues. The article titled "Salivary miRNA profiles identify children with autism spectrum disorder, correlate with adaptive behavior, and implicate ASD candidate genes involved in neurodevelopment" has found 14 differentially expressed miRNAs between TD and ASD children. Hence, based on their predictive performance they were chosen for analysis within the B&H population.

2\) It seems the authors are not even familiar with the statistical techniques you used in the manuscript. Cross validation (CV) was used because there is no replication study; however, this key word was not even clearly written.

The issue with clarifying the terminology regarding validation was addressed. The term cross validation is now used instead of using the term validation on its own (Line: 257-258; 392-394).

REWIER 3

1\) It seems that there may be confusion related to the training and validation sets, or at least the terminology used, which still may need clarification. Specifically, it appears as though the entire cohort was used as training less \~10% held back for validation. This was repeated through 'multiple iterations' (line 258) using the software. I would contend that this would generally be recognized as cross-validation and the paper should be clear at some point that validation is referring to cross validation, which is different from a fully withheld and independent validation set. Similar, a limitation outlining the need for a fully independent sample cohort for validation should be included.

As suggested by the reviewer, we have addressed the issue with using the term validation without stating it is cross validation. In materials and methods, we have changed validation to cross validation and have made clear that any type of validation which is mentioned later in the manuscript should be considered as a cross validation (Line: 257-258).

As suggested by the reviewer, we have addressed the limitation of the study regarding the need for an independent sample cohort for validation (Line: 392-394)

2\) The change of using the term spit to expectorant/expectorate is improper as it implies collection of phlegm and mucus from the lungs or throat rather than saliva (which it is meant to be reflected). This should be changed back to the previous wording (lines 107, 152).

As suggested by the reviewer, the wording in lines 107 and 152 was returned back to the previous wording and the word expectorate was replaced by saliva.

3\) Other corrections are required in the tables in S6, S8-S11 with respect to formatting and decimals.

Formatting corrections were made in the tables mentioned by the reviewer.

Thank you.
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Dear Dr. Hajdarpasic,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Lucia Billeci

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#3: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: There is no more comments.

There is no more comments.

There is no more comments.

There is no more comments.

Reviewer \#3: The concerns have been addressed. Clarity on cross-validation has improved and readers of the text should be able to distinguish that the validation herein refers to cross-validation. For clarity, I would suggest the term validation in the abstract (line 37) is written cross-validation.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#3: No
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Dear Dr. Hajdarpasic:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Lucia Billeci

Academic Editor

PLOS ONE
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